Question 1

What is the catalog number for 4- (1,15,15-trimethyl-3-azatetracyclo[10.2.1.0~2,11~.0~4,9~]pentadeca-2,4,6,8,10-pentaen-10-yl) morpho?

Accepted Answer

The catalog number for 4- (1,15,15-trimethyl-3-azatetracyclo[10.2.1.0~2,11~.0~4,9~]pentadeca-2,4,6,8,10-pentaen-10-yl) morpho is OR28236.

Question 2

Is 4- (1,15,15-trimethyl-3-azatetracyclo[10.2.1.0~2,11~.0~4,9~]pentadeca-2,4,6,8,10-pentaen-10-yl) morpho in stock?

Accepted Answer

4- (1,15,15-trimethyl-3-azatetracyclo[10.2.1.0~2,11~.0~4,9~]pentadeca-2,4,6,8,10-pentaen-10-yl) morpho is currently made to order / not held in immediate stock. Contact us for lead time.

Question 3

Can I request a Safety Data Sheet (SDS) for this product?

Accepted Answer

Yes, safety data sheets are available for hazardous or chemically classified products and can be provided on request or downloaded from the product page.

Question 4

Can this product be used for co-immunoprecipitation (Co-IP)?

Accepted Answer

Suitability for Co-IP depends on the specific antibody and is noted under validated applications on the datasheet. If it isn’t listed, contact our technical support team for guidance based on your target and sample type.

Question 5

Is this kit compatible with automated liquid handling platforms?

Accepted Answer

Automation compatibility varies by kit and isn’t always listed on the datasheet. Contact our technical support team with details of your platform so we can confirm with the manufacturer.

4- (1,15,15-trimethyl-3-azatetracyclo[10.2.1.0~2,11~.0~4,9~]pentadeca-2,4,6,8,10-pentaen-10-yl) morpho

Product Specifications

CAS Number

MDL Number

Smiles

Frequently Asked Questions

Explore Other Products

Anti-SYK Antibody Picoband®

Podocalyxin (3D3), CF568 conjugate, 0.1mg/mL

Estrogen Receptor (ER505), Biotin conjugate, 0.1mg/mL

Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/1948R), CF594 conjugate, 0.1mg/mL

NKX2.2 (Neuroendocrine & Ewing's Sarcoma Marker) (NX2/2198R), CF488A conjugate, 0.1mg/mL

Lhx2 Recombinant Rabbit Monoclonal Antibody [JE54-99]